Anxiety and depression in multiple sclerosis patients around diagnosis

Andrea Giordano, Franco Granella, Alessandra Lugaresi, Vittorio Martinelli, Maria Trojano, Paolo Confalonieri, Davide Radice, Alessandra Solari

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objectives: To prospectively identify anxiety and depressive symptoms, and their predictors, during the multiple sclerosis (MS) peridiagnostic period. Methods: The Hospital Anxiety and Depression Scale (HADS) was administered during diagnostic workup (baseline), and one and six months after diagnosis disclosure, to SIMS-Trial participants (ISRCTN81072971). Results: Of 197 screened patients, 120 (61%) were diagnosed with MS. At baseline, median HADS anxiety (HADS-A) score was 7.0 (interquartile range [IQR] 5.0-9.5), ≥ 8 (anxiety cut-off) in 43% (95% confidence interval [CI] 34%-52%). Median HADS depression (HADS-D) was 3.0 (IQR 1.0-5.0), ≥ 8 (depression cut-off) in 11% (95% CI 5%-16%). Independent predictors of anxiety were female sex (odds ratio [OR] 2.8, 95% CI 1.1-7.2) and HADS-D score (OR 20.8, 95% CI 2.5-175.5). The only predictor of depressive symptoms was HADS-A score (OR 20.0, 95% CI 2.8-260.9). Anxiety symptoms had decreased slightly but significantly (p <0.001) at six months. Depressive symptoms remained low. Conclusions: Anxiety was prominent in the period surrounding MS diagnosis disclosure, particularly in women. A slight but significant reduction occurred six months after diagnosis disclosure. Depressive symptoms were less common and stable over time. In addition to sex, depressive symptoms were the only variable independently associated with anxiety.

Original languageEnglish
Pages (from-to)86-91
Number of pages6
JournalJournal of the Neurological Sciences
Volume307
Issue number1-2
DOIs
Publication statusPublished - Aug 15 2011

Fingerprint

Multiple Sclerosis
Anxiety
Depression
Confidence Intervals
Disclosure
Odds Ratio
Sex Ratio

Keywords

  • Anxiety
  • Depression
  • Diagnosis
  • Hospital Anxiety and Depression Scale
  • Multiple sclerosis
  • Psychological screening

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Anxiety and depression in multiple sclerosis patients around diagnosis. / Giordano, Andrea; Granella, Franco; Lugaresi, Alessandra; Martinelli, Vittorio; Trojano, Maria; Confalonieri, Paolo; Radice, Davide; Solari, Alessandra.

In: Journal of the Neurological Sciences, Vol. 307, No. 1-2, 15.08.2011, p. 86-91.

Research output: Contribution to journalArticle

@article{3cf5795fd24e4817932dcd7883027c42,
title = "Anxiety and depression in multiple sclerosis patients around diagnosis",
abstract = "Objectives: To prospectively identify anxiety and depressive symptoms, and their predictors, during the multiple sclerosis (MS) peridiagnostic period. Methods: The Hospital Anxiety and Depression Scale (HADS) was administered during diagnostic workup (baseline), and one and six months after diagnosis disclosure, to SIMS-Trial participants (ISRCTN81072971). Results: Of 197 screened patients, 120 (61{\%}) were diagnosed with MS. At baseline, median HADS anxiety (HADS-A) score was 7.0 (interquartile range [IQR] 5.0-9.5), ≥ 8 (anxiety cut-off) in 43{\%} (95{\%} confidence interval [CI] 34{\%}-52{\%}). Median HADS depression (HADS-D) was 3.0 (IQR 1.0-5.0), ≥ 8 (depression cut-off) in 11{\%} (95{\%} CI 5{\%}-16{\%}). Independent predictors of anxiety were female sex (odds ratio [OR] 2.8, 95{\%} CI 1.1-7.2) and HADS-D score (OR 20.8, 95{\%} CI 2.5-175.5). The only predictor of depressive symptoms was HADS-A score (OR 20.0, 95{\%} CI 2.8-260.9). Anxiety symptoms had decreased slightly but significantly (p <0.001) at six months. Depressive symptoms remained low. Conclusions: Anxiety was prominent in the period surrounding MS diagnosis disclosure, particularly in women. A slight but significant reduction occurred six months after diagnosis disclosure. Depressive symptoms were less common and stable over time. In addition to sex, depressive symptoms were the only variable independently associated with anxiety.",
keywords = "Anxiety, Depression, Diagnosis, Hospital Anxiety and Depression Scale, Multiple sclerosis, Psychological screening",
author = "Andrea Giordano and Franco Granella and Alessandra Lugaresi and Vittorio Martinelli and Maria Trojano and Paolo Confalonieri and Davide Radice and Alessandra Solari",
year = "2011",
month = "8",
day = "15",
doi = "10.1016/j.jns.2011.05.008",
language = "English",
volume = "307",
pages = "86--91",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Anxiety and depression in multiple sclerosis patients around diagnosis

AU - Giordano, Andrea

AU - Granella, Franco

AU - Lugaresi, Alessandra

AU - Martinelli, Vittorio

AU - Trojano, Maria

AU - Confalonieri, Paolo

AU - Radice, Davide

AU - Solari, Alessandra

PY - 2011/8/15

Y1 - 2011/8/15

N2 - Objectives: To prospectively identify anxiety and depressive symptoms, and their predictors, during the multiple sclerosis (MS) peridiagnostic period. Methods: The Hospital Anxiety and Depression Scale (HADS) was administered during diagnostic workup (baseline), and one and six months after diagnosis disclosure, to SIMS-Trial participants (ISRCTN81072971). Results: Of 197 screened patients, 120 (61%) were diagnosed with MS. At baseline, median HADS anxiety (HADS-A) score was 7.0 (interquartile range [IQR] 5.0-9.5), ≥ 8 (anxiety cut-off) in 43% (95% confidence interval [CI] 34%-52%). Median HADS depression (HADS-D) was 3.0 (IQR 1.0-5.0), ≥ 8 (depression cut-off) in 11% (95% CI 5%-16%). Independent predictors of anxiety were female sex (odds ratio [OR] 2.8, 95% CI 1.1-7.2) and HADS-D score (OR 20.8, 95% CI 2.5-175.5). The only predictor of depressive symptoms was HADS-A score (OR 20.0, 95% CI 2.8-260.9). Anxiety symptoms had decreased slightly but significantly (p <0.001) at six months. Depressive symptoms remained low. Conclusions: Anxiety was prominent in the period surrounding MS diagnosis disclosure, particularly in women. A slight but significant reduction occurred six months after diagnosis disclosure. Depressive symptoms were less common and stable over time. In addition to sex, depressive symptoms were the only variable independently associated with anxiety.

AB - Objectives: To prospectively identify anxiety and depressive symptoms, and their predictors, during the multiple sclerosis (MS) peridiagnostic period. Methods: The Hospital Anxiety and Depression Scale (HADS) was administered during diagnostic workup (baseline), and one and six months after diagnosis disclosure, to SIMS-Trial participants (ISRCTN81072971). Results: Of 197 screened patients, 120 (61%) were diagnosed with MS. At baseline, median HADS anxiety (HADS-A) score was 7.0 (interquartile range [IQR] 5.0-9.5), ≥ 8 (anxiety cut-off) in 43% (95% confidence interval [CI] 34%-52%). Median HADS depression (HADS-D) was 3.0 (IQR 1.0-5.0), ≥ 8 (depression cut-off) in 11% (95% CI 5%-16%). Independent predictors of anxiety were female sex (odds ratio [OR] 2.8, 95% CI 1.1-7.2) and HADS-D score (OR 20.8, 95% CI 2.5-175.5). The only predictor of depressive symptoms was HADS-A score (OR 20.0, 95% CI 2.8-260.9). Anxiety symptoms had decreased slightly but significantly (p <0.001) at six months. Depressive symptoms remained low. Conclusions: Anxiety was prominent in the period surrounding MS diagnosis disclosure, particularly in women. A slight but significant reduction occurred six months after diagnosis disclosure. Depressive symptoms were less common and stable over time. In addition to sex, depressive symptoms were the only variable independently associated with anxiety.

KW - Anxiety

KW - Depression

KW - Diagnosis

KW - Hospital Anxiety and Depression Scale

KW - Multiple sclerosis

KW - Psychological screening

UR - http://www.scopus.com/inward/record.url?scp=79959812167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959812167&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2011.05.008

DO - 10.1016/j.jns.2011.05.008

M3 - Article

C2 - 21621796

AN - SCOPUS:79959812167

VL - 307

SP - 86

EP - 91

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -